Alligator Bioscience presents positive interim data

Alligator Bioscience’s CEO Søren Bregenholt visited BioStock’s studio to talk about the promising interim data from the OPTIMIZE-1 phase II trial with mitazalimab in pancreatic cancer.

The interim analysis shows an Objective Response Rate of 52 per cent and a Disease Control Rate of 91 per cent, further validating the potential of the drug candidate.